{"nctId":"NCT00789750","briefTitle":"Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus","startDateStruct":{"date":"2009-04"},"conditions":["Type 2 Diabetes Mellitus"],"count":562,"armGroups":[{"label":"Colesevelam","type":"EXPERIMENTAL","interventionNames":["Drug: Colesevelam","Drug: Pioglitazone"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Pioglitazone"]}],"interventions":[{"name":"Colesevelam","otherNames":["Welchol"]},{"name":"Placebo","otherNames":["No drug"]},{"name":"Pioglitazone","otherNames":["Actos"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of Type 2 diabetes mellitus\n* Inadequate glycemic control on a stable dose (at least 2 months prior to screening) of pioglitazone at 30 or 45 mg/day, with or without one or two other oral antidiabetic medications \\[metformin or a sulfonylurea, or dipeptidyl peptidase (DPP-IV) inhibitor\\]\n* Hemoglobin A1c (HbA1c) \\>= 7.5% and =\\< 9.5% at screening\n* Fasting plasma glucose =\\<240 mg/dL at randomization (Week 0/Day 1).\n* Male or female \\>= 18 years of age.\n* Women of childbearing potential must be using an adequate method of contraception as detailed per-protocol\n* Fasting C-peptide level \\>0.5 ng/mL at screening\n* Clinically stable in regards to medical conditions other than type 2 diabetes\n* Concomitant medications are at stable doses for at least 30 days prior to enrollment, and are not anticipated to need adjustment during the study period\n\nExclusion Criteria:\n\n* History of Type 1 diabetes and/or history of ketoacidosis\n* History of bowel obstruction\n* History of hypertriglyceridemia-induced pancreatitis\n* Fasting serum triglyceride concentration \\>500 mg/dL\n* History of dysphagia, swallowing disorders, gastroparesis, other gastrointestinal motility disorders, major gastrointestinal surgery\n* History of insulin use \\>= 2 weeks duration during the previous 3 months or a total of \\>2 months insulin therapy at any time prior to screening\n* Treatment with bile acid sequestrants, including colesevelam within 3 months prior to screening\n* Female subject who is pregnant or breastfeeding\n* History of unstable angina, myocardial infarction, cerebrovascular accident, transient ischemic attack, or any revascularization within 6 months prior to screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.34","spread":"0.083"},{"groupId":"OG001","value":"-0.02","spread":"0.083"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c at Week 4","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.28","spread":"0.037"},{"groupId":"OG001","value":"-0.11","spread":"0.037"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c at Week 8","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.35","spread":"0.055"},{"groupId":"OG001","value":"-0.14","spread":"0.056"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c at Week 16","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.50","spread":"0.078"},{"groupId":"OG001","value":"-0.15","spread":"0.078"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving an HbA1c Goal of <7.0%","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG)","description":"In this study a reduction in FPG of at least 30 mg/dL is considered glycemic response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.8","spread":"3.66"},{"groupId":"OG001","value":"9.9","spread":"3.66"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Decrease of >= 0.7 Percent in HbA1c","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":null},{"groupId":"OG001","value":"70","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Decrease of >= 0.5 Percent in HbA1c","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"147","spread":null},{"groupId":"OG001","value":"106","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Reduction in FPG of >= 30 mg/dL","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Cholesterol (TC)","description":"TC is measured in milligrams per deciliter (mg/dL)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"1.33"},{"groupId":"OG001","value":"3.1","spread":"1.32"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)","description":"LDL-C is measured in mg/dL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.1","spread":"2.14"},{"groupId":"OG001","value":"7.3","spread":"2.12"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)","description":"HDL-C is measured in mg/dL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"1.30"},{"groupId":"OG001","value":"1.1","spread":"1.30"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-HDL-C","description":"Non-HDL-C is measured in mg/dL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.2","spread":"1.85"},{"groupId":"OG001","value":"4.6","spread":"1.84"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Triglycerides (TG)","description":"TG are measured in mg/dL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.1","spread":null},{"groupId":"OG001","value":"2.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein A-1 (Apo A-I)","description":"Apo A-1 is measured in mg/dL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"0.92"},{"groupId":"OG001","value":"-0.2","spread":"0.92"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein B (Apo B)","description":"Apo B is measured in mg/dL","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.2","spread":"1.51"},{"groupId":"OG001","value":"3.6","spread":"1.51"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Insulin Levels","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"1.76"},{"groupId":"OG001","value":"0.8","spread":"1.76"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting C-peptide","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.10"},{"groupId":"OG001","value":"0.3","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)","description":"HOMA-IR is a calculation of fasting insulin and fasting glucose that shows the level of insulin resistance. Lower numbers are better.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.71"},{"groupId":"OG001","value":"0.3","spread":"0.72"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":274},"commonTop":["Hypoglycaemia"]}}}